Bristol Myers Squibb (CELG-RI) Divestments (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Divestments of $209.0 million for Q2 2026, down 22.59% year-over-year from $270.0 million in Q2 2025, and down 33.01% quarter-over-quarter from $312.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Divestments (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Divestments for 18 consecutive years, with $209.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Divestments fell 22.59% year-over-year to $209.0 million; the TTM figure through Jun 2026 stood at $1.1 billion (down 2.0% YoY), while the FY2025 annual figure was $1.1 billion, down 2.55% from the prior year.
- Divestments fell to $209.0 million in Q2 2026 per CELG-RI's latest filing, from $312.0 million in the prior quarter.
- Across five years, Divestments topped out at $490.0 million in Q4 2022 and bottomed at $192.0 million in Q2 2022.
- Historically, Divestments has averaged $272.5 million across 5 years, with a median of $251.0 million in 2023.
- Annual changes were most pronounced in 2022 — Divestments soared 175.28% — and 2023, when it plunged 50.82%.
- Bristol Myers Squibb's Divestments stood at $490.0 million in 2022, then slumped by 50.82% to $241.0 million in 2023, then surged by 38.17% to $333.0 million in 2024, then declined by 16.22% to $279.0 million in 2025, then retreated by 25.09% to $209.0 million in 2026.
- Business Quant data shows CELG-RI's Divestments at $209.0 million in Q2 2026, $312.0 million in Q1 2026, and $279.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | - |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | - |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 62.00 Mn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | - |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 1.88 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 209.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 209.00 Mn |
| Mar 31, 2026 | 312.00 Mn |
| Dec 31, 2025 | 279.00 Mn |
| Sep 30, 2025 | 279.00 Mn |
| Jun 30, 2025 | 270.00 Mn |
| Mar 31, 2025 | 243.00 Mn |
| Dec 31, 2024 | 333.00 Mn |
| Sep 30, 2024 | 255.00 Mn |
| Jun 30, 2024 | 270.00 Mn |
| Mar 31, 2024 | 241.00 Mn |
| Dec 31, 2023 | 241.00 Mn |
| Sep 30, 2023 | 247.00 Mn |
| Jun 30, 2023 | 194.00 Mn |
| Mar 31, 2023 | 227.00 Mn |
| Dec 31, 2022 | 490.00 Mn |
| Sep 30, 2022 | 221.00 Mn |
| Jun 30, 2022 | 192.00 Mn |
| Mar 31, 2022 | 402.00 Mn |
| Dec 31, 2021 | 178.00 Mn |
| Sep 30, 2021 | 188.00 Mn |